Table 1.
Demographic, clinical, and COVID-19 third vaccine dose immune-related variables
| Study population | MS patients N = 20 |
||
|---|---|---|---|
| Group 1 fingolimod-continuation N = 10 | Group 2 fingolimod-discontinuation N = 10 | p | |
| Gender, n (%) | |||
| Females | 8 (80.0) | 4 (40.0) | |
| Males | 2 (20.0) | 6 (60.0) | |
| Age, years | |||
| Median | 51.6 | 47.5 | 0.69 |
| 25–75 IQR | 46.9–58.1 | 43.0–54.9 | |
| Disease duration, years | |||
| Median | 20.9 | 15.9 | 0.10 |
| 25–75 IQR | 18.3–23.5 | 6.5–18.9 | |
| Disability by EDSS | |||
| Median | 2.25 | 2.0 | 0.89 |
| 25–75 IQR | 1.1–2.9 | 1.5–3.6 | |
| Fingolimod Tx duration, years | |||
| Median | 7.25 | 4.8 | 0.15 |
| 25–75 IQR | 5.6–8.3 | 2.5 -8.4 | |
| Time from 2nd to 3rd vaccine dose, months | |||
| Median | 6.6 | 6.2 | |
| 25–75 IQR | 6.4–7.5 | 6.1–6.2 | NS |
| Time without fingolimod treatment, months | |||
| Median | 4.2 | ||
| 25–75 IQR | 2.5–4.4 | ||
| ALC at 3rd vaccine dose cells/mm3 | |||
| Median | 775 | 1510 | < 0.0001 |
| 25–75 IQR | 572–817 | 1190–1668 | |
|
Patients with positive SARS-COV-2 IgG, 1 month N, (%) |
2 (20) | 8 (80) | |
| SARS-COV-2 IgG titer, BAU/ml, 1 month | |||
| Median | 26.4 | 202.3 | 0.022 |
| 25–75 IQR | 3.5–29.7 | 49.3–580.4 | |
|
Patients with positive SARS-COV-19 IgG, 3 months N, (%) |
2 (20) | 6 (60) | |
| SARS-COV-2 IgG titer, BAU/ml, 3 months | |||
| Median | 12.1 | 115 | 0.0296 |
| 25–75 IQR | 4.8–18.4 | 23.3–269.8 | |
| % SARS-COV-2 IgG decay within 3 months | 46.2 | 34.9 | |